hi fellow Fools,here are the data of the CRPC trial reported @ ESMO 2012 - already posted on Fool.com:http://www.dailyfinance.com/2012/09/30/interim-data-for-cabo...My take:1) the study design was a non-randomized expansion of a phase 2 randomized discontinuation study - this means that all patients were already treated with Cabo and had no severe tolerability issues.2) Encouraging: the dose of 40 mg seems to be as effective as 100 mg once daily.3) Outstanding effect: 67% (26 of 39 pats.) showed a >=30% decrease in their circulating tumor cells - but why only 39 patients out of the initially 51 enrolled ? I have to dig deeper into the published data to answer this discrepancy.So far no negative news for Cabo - IMO, nothing that could make EXEL shares plummet ahead of a probable MTC approval (in 2 to 3 weeks ?).fool on,marsuculix
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat